CIDARA THERAPEUTICS INC

NASDAQ: CDTX (Cidara Therapeutics, Inc.)

最近更新时间: 2天之前, 6:08AM

109.03

4.35 (4.16%)

前收盘价格 104.68
收盘价格 103.50
成交量 1,190,635
平均成交量 (3个月) 825,323
市值 2,764,788,480
预期市盈率 (P/E Forward) 5.75
价格/销量 (P/S) 0.990
股市价格/股市净资产 (P/B) 4.98
52周波幅
12.66 (-88%) — 121.21 (11%)
利润日期 6 Nov 2025
营业利益率 (TTM) -35,743.71%
稀释每股收益 (EPS TTM) -26.68
季度收入增长率 (YOY) -100.00%
总债务/股东权益 (D/E MRQ) 1.89%
流动比率 (MRQ) 3.87
营业现金流 (OCF TTM) -191.84 M
杠杆自由现金流 (LFCF TTM) -81.87 M
资产报酬率 (ROA TTM) -55.20%
股东权益报酬率 (ROE TTM) -299.58%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Cidara Therapeutics, Inc. 看涨 看涨

AIStockmoo 评分

0.8
分析师共识 1.5
内部交易活动 NA
价格波动 -3.0
技术平均移动指标 2.5
技术振荡指标 2.0
平均 0.75

相关股票

股票 市值 DY P/E(TTM) P/B
CDTX 3 B - - 4.98
RNA 10 B - - 5.40
PTCT 5 B - 9.52 -
CRNX 4 B - - 3.34
IRON 3 B - - 3.73
OCUL 2 B - - 7.66

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 1.12%
机构持股比例 73.93%

所有权

姓名 日期 持有股份
Darwin Global Management, Ltd. 30 Jun 2025 768,424
52周波幅
12.66 (-88%) — 121.21 (11%)
目标价格波幅
100.00 (-8%) — 200.00 (83%)
200.00 (JP Morgan, 83.44%) 购买
173.00 (58.67%)
100.00 (Needham, -8.28%) 购买
平均值 168.43 (54.48%)
总计 7 购买
平均价格@调整类型 100.63
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 21 Oct 2025 150.00 (37.58%) 购买 103.22
09 Oct 2025 150.00 (37.58%) 购买 110.76
Morgan Stanley 16 Oct 2025 190.00 (74.26%) 购买 102.02
JP Morgan 10 Oct 2025 200.00 (83.44%) 购买 113.05
WBB Securities 09 Oct 2025 199.00 (82.52%) 购买 110.76
24 Sep 2025 123.00 (12.81%) 购买 88.58
JMP Securities 03 Oct 2025 173.00 (58.67%) 购买 101.99
08 Aug 2025 66.00 (-39.47%) 购买 62.00
Guggenheim 25 Sep 2025 167.00 (53.17%) 购买 84.76
Needham 24 Sep 2025 100.00 (-8.28%) 购买 88.58
08 Aug 2025 74.00 (-32.13%) 购买 62.00
显示更多

该时间范围内无数据。

日期 类型 细节
28 Oct 2025 公告 Cidara Therapeutics to Participate in November Investor Conferences
23 Oct 2025 公告 Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
23 Oct 2025 公告 Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
21 Oct 2025 公告 Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
13 Oct 2025 公告 Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
10 Oct 2025 公告 Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
09 Oct 2025 公告 Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
02 Oct 2025 公告 Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
25 Sep 2025 公告 Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
24 Sep 2025 公告 Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
17 Sep 2025 公告 Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
04 Sep 2025 公告 Cidara Therapeutics to Participate in September Investor Conferences
03 Sep 2025 公告 Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
07 Aug 2025 公告 Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票